Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : MP Healthcare
Deal Size : $13.0 million
Deal Type : Financing
Draupnir Bio Completes 12M Seed Round to Advance Oral Small Molecule Degraders
Details : The proceeds from the financing will be used to further develop Draupnir’s risk-diversified preclinical pipeline of oral, small molecule protein degraders, which have been proven against targets.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : MP Healthcare
Deal Size : $13.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?